Vera Therapeutics (VERA) Cash from Financing Activities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Cash from Financing Activities data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 157.14% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311.3 million (down 6.14% YoY) and the FY2025 annual result came in at $308.9 million, down 49.08% from the prior year.
• Cash from Financing Activities fell to $3.9 million in Q1 2026, from $286.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $326.0 million in Q4 2024 to a low of $48000.0 in Q2 2022.
• A 5-year average of $67.9 million and a median of $3.9 million in 2026 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 286771.43% in 2022, down 99.9% in 2022.
• Tracing VERA's Cash from Financing Activities over 5 years: stood at $20.7 million in 2022, then grew by 19.89% to $24.8 million in 2023, then soared by 1212.85% to $326.0 million in 2024, then retreated by 12.17% to $286.3 million in 2025, then tumbled by 98.62% to $3.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.9 million (Q1 2026), $286.3 million (Q4 2025), and $797000.0 (Q3 2025), per Business Quant data.